Articles

The year 2020 was an unprecedented year, bringing significant changes in the practice of medicine and knowledge sharing at scientific forums. National and international meetings, such as the European Hematological Association (EHA) and the American Society of Hematology (ASH), pivoted to facilitate the dissemination of information regarding cutting-edge research and treatment advances in a virtual format. Read More ›

Based on interim results from the STOMP study in patients with relapsed/refractory multiple myeloma (RRMM) who are heavily pretreated, the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates (ORRs) and encouraging progression-free survival (PFS). Read More ›

In patients with relapsed/refractory multiple myeloma (RRMM), preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab show manageable toxicity, moderate efficacy overall, and higher efficacy for those with t(11;14). Read More ›

An ongoing phase 1/2, nonrandomized, multicenter study is exploring the safety profile, efficacy, and pharmacokinetics of adding daratumumab to venetoclax and dexamethasone with or without bortezomib for patients with relapsed/refractory multiple myeloma (RRMM) who have a t(11;14) abnormality. Read More ›

BELLINI was a phase 3, randomized, double-blind, multicenter study designed to investigate the efficacy and safety of venetoclax + bortezomib + dexamethasone versus bortezomib + dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Read More ›

Encouraging and well-tolerated treatment efficacy was shown in patients with relapsed/refractory multiple myeloma (RRMM) in this analysis of updated efficacy and safety data from the ANCHOR study of melphalan flufenamide (melflufen) plus dexamethasone and daratumumab or bortezomib. Read More ›

Patients with relapsed/refractory multiple myeloma (RRMM) who have had ≥2 prior lines of therapy, including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI), and who were refractory to pomalidomide and/or an anti-CD38 monoclonal antibody were evaluated in a phase 2 single-arm, multicenter study known as HORIZON. Read More ›

Based on a phase 2 trial, interim results exploring the response to ixazomib, lenalidomide, and dexamethasone (IRd) induction followed by a single autologous stem-cell transplantation (ASCT), IRd consolidation, and risk-based maintenance found a 93% overall response rate (ORR). Read More ›

TOURMALINE-MM4 is an international, multicenter, double-blind, placebo-controlled, phase 3 study that examined the efficacy and safety profile of oral ixazomib as maintenance therapy in patients with newly diagnosed multiple myeloma (NDMM) who have not undergone stem-cell transplantation after initial treatment and its impact on progression-free survival (PFS) compared with those taking placebo. Read More ›

The randomized FORTE trial showed that patients who were newly diagnosed with transplant-eligible multiple myeloma (MM) experienced significantly improved progression-free survival (PFS) with carfilzomib plus lenalidomide-dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib plus cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation. Read More ›